For most of the 2010s, India's clinical trial framework had a reputation problem: approval timelines were unpredictable, responsibilities were scattered across amendments to Schedule Y, and sponsors routinely routed studies to other geographies rather than wait. The New Drugs and Clinical Trials Rules 2019 (NDCT Rules), notified on 19 March 2019 under the Drugs and Cosmetics Act 1940, were written to fix that. They replaced the older Schedule Y-era provisions with a single, self-contained rulebook covering new drugs, investigational new drugs, clinical trials, bioavailability and bioequivalence studies, and ethics committees.
Seven years on, the NDCT Rules are the operating manual for anyone sponsoring a trial in India. This guide summarises what changed, the timelines that matter, and the obligations sponsors take on when they sign a protocol.
What Changed in 2019
The NDCT Rules did more than consolidate old provisions. The substantive shifts sponsors should know:
- Defined review timelines with consequences. Applications now carry statutory decision clocks, including a deemed-approval mechanism for drugs developed in India (detailed below).
- Mandatory ethics committee registration. No ethics committee may oversee a trial without registration from the Central Licensing Authority, and committee composition rules were tightened.
- A codified compensation framework. Compensation for trial-related injury or death is calculated under the Seventh Schedule, with fixed payment deadlines, and sponsors must provide free medical management to affected participants.
- Pre-submission meetings. Sponsors can formally meet CDSCO before filing to align on data expectations, which reduces query cycles later.
- Post-trial access. With ethics committee recommendation and the participant's consent, a sponsor may continue to provide the investigational drug free of charge after the trial where no alternative therapy exists.
- An academic carve-out. Academic studies using an approved drug for a new indication do not need DCGI permission when the results are not intended for regulatory submission and the ethics committee approves the study.
- Clearer definitions. "New drug", "investigational new drug" and "orphan drug" received precise definitions, and a drug retains new drug status for four years from first approval.
The 90-Working-Day Timeline, and When 30 Days Applies
The headline reform is the review clock. For a standard clinical trial application, filed in Form CT-04 through the SUGAM portal, the Central Licensing Authority must convey its decision within 90 working days of receiving the application.
For drugs discovered, researched and developed in India, the clock is 30 working days, and it has teeth: if the authority sends no communication within that window, permission is deemed to have been granted. This deemed-approval provision was designed to make India-origin innovation faster to test at home, and it removed the open-ended silence that older applications could fall into.
Two cautions. First, the clock runs in working days, so 90 working days is roughly four to five calendar months. Second, a substantive query from CDSCO restarts meaningful work on the sponsor's side; slow query responses, not slow regulators, are now the most common source of delay.
Key NDCT 2019 Timelines
| Milestone | Timeline under the NDCT Rules 2019 |
|---|---|
| Clinical trial application review (standard) | 90 working days |
| Drugs discovered and developed in India | 30 working days, deemed approval if no communication |
| Ethics committee registration decision | 45 working days |
| Ethics committee registration validity | 5 years |
| Investigator report of a serious adverse event | Within 24 hours of occurrence |
| Sponsor's analysed SAE report to the authority and ethics committee | Within 14 days of knowledge |
| Payment of compensation after an order | Within 30 days |
Ethics Committee Requirements
The rules professionalised ethics oversight, and sponsors are expected to verify committee credentials before site selection. An ethics committee for clinical trial must:
- Have at least seven members drawn from medical, non-medical, scientific and non-scientific backgrounds, including a lay person and a woman member
- Keep at least half its members unaffiliated with the institution where it sits
- Hold a valid registration from the Central Licensing Authority, which remains valid for five years
- Report changes in its membership to the authority within 30 days
- Retain trial records for five years after completion
A trial cannot begin at a site until the registered committee has approved the protocol, and the committee retains ongoing oversight, including the power to review serious adverse events and recommend compensation.
Sponsor Obligations Under the NDCT Rules
Sponsorship under the 2019 rules is an active legal role, not a funding label. The core duties:
- Conduct to GCP. Trials must follow the approved protocol and Good Clinical Practice guidelines, with the sponsor responsible for monitoring, data integrity and investigational product supply.
- Registration before enrolment. The trial must be registered with the Clinical Trials Registry - India (CTRI) before the first participant is enrolled.
- Safety reporting. Investigators report serious adverse events within 24 hours; the sponsor must submit its analysed report to the Central Licensing Authority and the ethics committee within 14 days of knowledge of the event.
- Medical management and compensation. Participants injured in a trial receive free medical management for as long as required, or until it is established the injury is unrelated to the trial. Where injury or death is trial-related, compensation is calculated under the Seventh Schedule formula and must be paid within 30 days of the order.
- Reporting and record-keeping. Sponsors submit trial status updates, notify the authority of premature termination with reasons, and maintain records for inspection.
These duties follow the sponsor even when execution is delegated. Choosing an experienced execution partner for patient-based clinical trials matters precisely because regulatory accountability cannot be outsourced.
Rule 101: When Local Trials Can Be Waived
Rule 101 gives the Central Licensing Authority discretion to waive the local clinical trial requirement for a new drug already approved in specified countries. By an order dated 7 August 2024, CDSCO named the United States, United Kingdom, Japan, Australia, Canada and the European Union for this purpose, for defined categories: orphan drugs, cell and gene therapies, new drugs for pandemic situations or special defence use, and drugs offering significant therapeutic advantage over existing care.
The waiver is discretionary, not automatic, and typically comes with post-approval commitments such as phase IV studies in India. For sponsors of eligible products, it can compress market entry by a year or more, so the eligibility analysis belongs early in the India strategy.
Practical Filing Tips for Sponsors
Hard-won lessons from applications that went smoothly, and some that did not:
- Use the pre-submission meeting. Agreeing the data package with CDSCO before filing prevents the most expensive category of query.
- File a complete Form CT-04 dossier the first time. Chemistry and manufacturing data, non-clinical summaries, the investigator brochure and protocol should be internally consistent before submission; reviewers notice mismatched version numbers.
- Verify every site's ethics committee registration and expiry date during feasibility, not after site initiation.
- Align the protocol and SOPs with the current ICH E6 (R3) good clinical practice framework; the rules expect GCP conduct and inspections test it.
- Build the SAE reporting chain before first enrolment. The 24-hour and 14-day clocks leave no room to design a process mid-trial.
- Track the review clock and respond to queries within days, not weeks. The statutory timeline protects sponsors who keep their side of the file moving.
Frequently Asked Questions
When did the NDCT Rules 2019 come into force? They were notified on 19 March 2019 and apply to new drugs, investigational new drugs, clinical trials, BA/BE studies and ethics committees in India.
What is deemed approval under the NDCT Rules? For drugs discovered, researched and developed in India, if the Central Licensing Authority does not respond to a clinical trial application within 30 working days, permission is treated as granted and the sponsor may proceed.
Do academic clinical trials need DCGI permission? No, provided the study uses an approved drug, the results are not intended for regulatory submission, and a registered ethics committee has approved it.
What compensation must sponsors provide for trial injuries? Free medical management for as long as required, plus financial compensation calculated under the Seventh Schedule where the injury or death is trial-related, payable within 30 days of the compensation order.
Run Your India Trial with a Team That Knows the Rulebook
Celesta Healthcare's clinical research division runs Phase I to IV programmes on ICH E6 (R3)-compliant processes, with a pan-India investigator network and in-house regulatory support for the filings the NDCT Rules demand. If you are planning a study, start with our patient-based clinical trials services, or ask our regulatory team to map your DCGI and CDSCO approval pathway before you file. A short scoping call is usually enough to give you a realistic timeline and budget.